Starting Injectable Buprenorphine in Persons Hospitalized with OUD & Infections
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Starting Injectable Buprenorphine in Persons Hospitalized with OUD & Infections
Recorded: Thursday, April 13, 2023 to Sunday, April 16, 2023
On-Demand Session
Overview
This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the common infections that patients with OUD present within a hospital setting and how to rapidly screen & diagnose OUD and initiate MOUD including injectable buprenorphine treatment while managing concurrent infections.
Panelists will discuss real-world challenges in the process of initiating Long acting buprenorphine (LAB) in persons hospitalized with infections and OUD through an ongoing NIH funded multisite trial. To be discussed: the national epidemiology of intersecting epidemics; the clinical trial strategy to optimally time LAB dosing in the setting of ongoing infection; low dose sublingual buprenorphine to transition from methadone/other opioids to LAB; impact of COVID19 on overdose/MOUD access; and collaboration models in hospital settings to mange these duel diseases.
The target audience for this intermediate level session includes physicians, nurse practitioners, physician assistants, other clinicians, researchers, residents, fellows, students, and counselors.
This session addresses the following ACGME Competencies: Patient Care and Procedural Skills, Medical Knowledge
This session addresses the following IOM Competencies:Provide patient-centered care, Work in interdisciplinary teams, Employ evidence-based practice
Learning Objectives
Upon completion, learners will be able to:
- understand the common infections that patients with OUD present with in a hospital setting and how to rapidly screen & diagnose OUD and initiate MOUD including injectable buprenorphine treatment while managing concurrent infections.
- know how to use low dose transitions of opioid agonist treatments in persons on methadone or buprenorphine to start long-acting buprenorphine (LAB) in the hospital setting and how to co-manage pain disorders.
- know how to best collaborate with Addiction Psychiatry/ Addiction Medicine and Infectious Disease services in order to best serve patients hospitalized with OUD and infections including during the COVID19 pandemic
Registration Rates
| Rate Description | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM e-Learning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 05/15/2026
Session Instructions
- Click on the Contents tab to watch the on-demand recording.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer Essential Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Sandra Springer
MD
Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases, and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System, where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from the University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD).
No relevant financial relationships
Alain H. Litwin
MD, MPH
Alain Litwin, MD, MPH is Vice Chair of Academics and Research and Professor of Medicine at Greenville Health System, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he is launching a Center for Addiction and Prevention Research. He is board certified in internal medicine and addiction medicine, and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000. As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx. With funding from NIH, PCORI, CMS, CDC, AHRQ, the Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of HCV care, and on advocating for increasing access to effective care for all HCV-infected patients.
Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with the New York City Department of Health and Mental Hygiene, New York State Department of Health, Substance Abuse and Mental Health Service Administration, Center for Substance Abuse Treatment, American Association for the Treatment of Opioid Dependence, and the American Society of Addiction Medicine. Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).
No relevant financial relationships
Manesh Gopaldas, MD
T32 Addiction Psychiatry Fellow
Columbia University
Dr. Manesh Gopaldas is a second-year T32 Addiction Psychiatry Fellow at Columbia University. His area of focus is health services research and his goal is to improve delivery of care and health outcomes for people with substance use disorders (SUDs). Under the mentorship of Drs. Edward Nunes and Aimee Campbell, Dr. Gopaldas is studying patient-centered engagement and retention in care of people with SUDs. His current projects have examined topics such as the association between increases in adherence to medications for opioid use disorder (MOUD) and specific types of healthcare resource utilization over time and the impact of MOUD on patient-centered goals.
.jpg "Speaker image")
Michelle Strong, DNP, FNP-BC, CARN-AP
Nurse Practitioner - Addiction Medicine Center
Prisma Health
Michelle Strong DNP, MSN, FNP- BC, CARN-AP is a Family Nurse Practitioner, certified in Addiction Medicine, at the Prisma Health Addiction Medicine Center in Greenville, SC. She helped build, launch, and currently serves as the Clinical Lead on Prisma Health’s Inpatient Addiction Medicine Consult Team and is the Project Director for the NIH funded COMMIT study. She has a background working in both adult and pediatric ICU and has worked with vulnerable pediatric populations in Alaska. Her research interests include the impact of fitness on mental health and substance use and the exploration of a functional medicine approach on patient’s perceived state of health. Strong is a two-time graduate of Emory University with a BS in biology/sociology and a BSN in nursing. She completed her MSN, graduating with honors in 2019 and recently finished her Doctorate of Nursing Practice with a concentration in Executive Health Systems Leadership at the University of Arizona in December of 2022.
Email: Michelle.Strong@prismahealth.org
.jpg "Speaker image")
Prerana Roth, MD, MPH
Infectious Disease Physician
Prisma Health
Prerana Roth, MD, MPH is an Infectious Disease specialist at Prisma Health Upstate in Greenville, SC. She is also board certified in addiction medicine as well. Her clinical and research interests are to optimize care for HIV, Hepatitis C, and substance use disorder. She graduated from Northwestern University's Feinberg School of Medicine in 2008 and completed internal medicine residency and infectious disease fellowships at University of Illinois at Chicago in 2013.
Dr. Kathleen T. Brady
MD, PhD
Dr. Brady is an experienced clinical and translational researcher and has been conducting scientific investigations and clinical work in the field of addictions and psychiatric disorders for over 30 years. Her research focuses on pharmacotherapy of substance use disorders, comorbidity of psychiatric disorders and addictions (e.g., posttraumatic stress disorder and bipolar disorder), gender differences and women’s issues in addictions, and the neurobiologic connections between stress and addictions. She has received numerous federal research grants and has published over 300 peer-reviewed journal articles and co-edited 10 books. She is the Vice President for Research at the Medical University of South Carolina. She is the principal Investigator of MUSC’s Clinical and Translational Science Award (CTSA), Principal Investigator of the Southern Consortium Node of the NIDA-funded Clinical Trials Network and Director of MUSC’s Women’s Research Center. Her dedication to furthering research careers has attracted a number of junior investigators and clinicians. She has served at the President of the Association for Medical Education and Research in Substance Use Disorders (AMERSA), the American Academy of Addiction Psychiatry (AAAP) and is currently the President of the International Society of Addiction Medicine (ISAM).
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification / Continuing Certification Program
American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for 1.25 credits towards ABPM MOC Part II requirements.
American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.
American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
Royal College of Physicians and Surgeons of Canada (RCPSC)
Royal College Fellows can use participation in Accredited Continuing Medical Education to earn Section 3 Credits.
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee members and Presenters have disclosed relevant financial relationship information. The ASAM CE Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Key:
Complete
Next
Failed
Available
Locked